311 related articles for article (PubMed ID: 23736154)
1. Synergistic interactions between camptothecin and EGFR or RAC1 inhibitors and between imatinib and Notch signaling or RAC1 inhibitors in glioblastoma cell lines.
Sooman L; Ekman S; Andersson C; Kultima HG; Isaksson A; Johansson F; Bergqvist M; Blomquist E; Lennartsson J; Gullbo J
Cancer Chemother Pharmacol; 2013 Aug; 72(2):329-40. PubMed ID: 23736154
[TBL] [Abstract][Full Text] [Related]
2. Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines.
Avramis IA; Laug WE; Sausville EA; Avramis VI
Cancer Chemother Pharmacol; 2003 Oct; 52(4):307-18. PubMed ID: 12827297
[TBL] [Abstract][Full Text] [Related]
3. In vitro novel combinations of psychotropics and anti-cancer modalities in U87 human glioblastoma cells.
Tzadok S; Beery E; Israeli M; Uziel O; Lahav M; Fenig E; Gil-Ad I; Weizman A; Nordenberg J
Int J Oncol; 2010 Oct; 37(4):1043-51. PubMed ID: 20811727
[TBL] [Abstract][Full Text] [Related]
4. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
[TBL] [Abstract][Full Text] [Related]
5. Momelotinib sensitizes glioblastoma cells to temozolomide by enhancement of autophagy via JAK2/STAT3 inhibition.
Liu T; Li A; Xu Y; Xin Y
Oncol Rep; 2019 Mar; 41(3):1883-1892. PubMed ID: 30664175
[TBL] [Abstract][Full Text] [Related]
6. Combined inhibition of HER1/EGFR and RAC1 results in a synergistic antiproliferative effect on established and primary cultured human glioblastoma cells.
Karpel-Massler G; Westhoff MA; Zhou S; Nonnenmacher L; Dwucet A; Kast RE; Bachem MG; Wirtz CR; Debatin KM; Halatsch ME
Mol Cancer Ther; 2013 Sep; 12(9):1783-95. PubMed ID: 23832120
[TBL] [Abstract][Full Text] [Related]
7. Cytotoxic and apoptotic effects of bortezomib and gefitinib compared to alkylating agents on human glioblastoma cells.
Pédeboscq S; L'Azou B; Passagne I; De Giorgi F; Ichas F; Pometan JP; Cambar J
J Exp Ther Oncol; 2008; 7(2):99-111. PubMed ID: 18771084
[TBL] [Abstract][Full Text] [Related]
8. EFEMP1 induces γ-secretase/Notch-mediated temozolomide resistance in glioblastoma.
Hiddingh L; Tannous BA; Teng J; Tops B; Jeuken J; Hulleman E; Boots-Sprenger SH; Vandertop WP; Noske DP; Kaspers GJ; Wesseling P; Wurdinger T
Oncotarget; 2014 Jan; 5(2):363-74. PubMed ID: 24495907
[TBL] [Abstract][Full Text] [Related]
9. HDAC6 promotes cell proliferation and confers resistance to temozolomide in glioblastoma.
Wang Z; Hu P; Tang F; Lian H; Chen X; Zhang Y; He X; Liu W; Xie C
Cancer Lett; 2016 Aug; 379(1):134-42. PubMed ID: 27267806
[TBL] [Abstract][Full Text] [Related]
10. The unfolded protein response regulator GRP78/BiP as a novel target for increasing chemosensitivity in malignant gliomas.
Pyrko P; Schönthal AH; Hofman FM; Chen TC; Lee AS
Cancer Res; 2007 Oct; 67(20):9809-16. PubMed ID: 17942911
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of neoadjuvant imatinib in glioblastoma: evaluation of clinical and molecular effects of the treatment.
Razis E; Selviaridis P; Labropoulos S; Norris JL; Zhu MJ; Song DD; Kalebic T; Torrens M; Kalogera-Fountzila A; Karkavelas G; Karanastasi S; Fletcher JA; Fountzilas G
Clin Cancer Res; 2009 Oct; 15(19):6258-66. PubMed ID: 19789313
[TBL] [Abstract][Full Text] [Related]
12. In vitro cytotoxic effects of imatinib in combination with anticancer drugs in human prostate cancer cell lines.
Kübler HR; van Randenborgh H; Treiber U; Wutzler S; Battistel C; Lehmer A; Wagenpfeil S; Hartung R; Paul R
Prostate; 2005 Jun; 63(4):385-94. PubMed ID: 15617027
[TBL] [Abstract][Full Text] [Related]
13. Combination of sublethal concentrations of epidermal growth factor receptor inhibitor and microtubule stabilizer induces apoptosis of glioblastoma cells.
Failly M; Korur S; Egler V; Boulay JL; Lino MM; Imber R; Merlo A
Mol Cancer Ther; 2007 Feb; 6(2):773-81. PubMed ID: 17308073
[TBL] [Abstract][Full Text] [Related]
14. MiR-203 downregulation is responsible for chemoresistance in human glioblastoma by promoting epithelial-mesenchymal transition via SNAI2.
Liao H; Bai Y; Qiu S; Zheng L; Huang L; Liu T; Wang X; Liu Y; Xu N; Yan X; Guo H
Oncotarget; 2015 Apr; 6(11):8914-28. PubMed ID: 25871397
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
Tsurutani J; West KA; Sayyah J; Gills JJ; Dennis PA
Cancer Res; 2005 Sep; 65(18):8423-32. PubMed ID: 16166321
[TBL] [Abstract][Full Text] [Related]
16. Combined gefitinib and pemetrexed overcome the acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Wu M; Yuan Y; Pan YY; Zhang Y
Mol Med Rep; 2014 Aug; 10(2):931-8. PubMed ID: 24840891
[TBL] [Abstract][Full Text] [Related]
17. The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner.
Chakravarti A; Chakladar A; Delaney MA; Latham DE; Loeffler JS
Cancer Res; 2002 Aug; 62(15):4307-15. PubMed ID: 12154034
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of imatinib mesylate against uveal melanoma in vitro and in vivo.
Triozzi PL; Aldrich W; Dombos C
Melanoma Res; 2008 Dec; 18(6):420-30. PubMed ID: 18971787
[TBL] [Abstract][Full Text] [Related]
19. Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series.
Dresemann G
Ann Oncol; 2005 Oct; 16(10):1702-8. PubMed ID: 16033874
[TBL] [Abstract][Full Text] [Related]
20. Synergistic antiproliferative effect of imatinib and adriamycin in platelet-derived growth factor receptor-expressing osteosarcoma cells.
Yamaguchi SI; Ueki A; Sugihara E; Onishi N; Yaguchi T; Kawakami Y; Horiuchi K; Morioka H; Matsumoto M; Nakamura M; Muto A; Toyama Y; Saya H; Shimizu T
Cancer Sci; 2015 Jul; 106(7):875-82. PubMed ID: 25940371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]